Yellow Fever Virus NS1 protein
January 2014. NAC announces the release of its Yellow Fever Virus (YFV) NS1 protein derived from a human cell line.
Production of YFV-NS1 protein is based entirely on human cell lines using state-of-the-art expression techniques, the same approach which NAC used to develop its well received DENV NS1 serotypes.
The YFV-NS1 protein has been manufactured in response to the unmet need for a highly purified, concentrated protein for use in further vaccine development and serological based diagnostic assays. The detection of the NS1 protein offers much higher fidelity across multiple flaviviruses where cross-reactivity can otherwise pose an issue.
Yellow fever continues to be a public health concern in many countries of Africa and the Americas. It is estimated that 200 000 cases and 30 000 deaths are attributable to yellow fever annually.
World First: All 4 Dengue Virus NS1 Serotypes from human cell lines
29/09/13. The Native Antigen Company (NAC) announces a world first: the release of all 4 Dengue Virus NS1 serotypes from human cell lines. All four DENV NS1 serotypes have been manufactured in response to the unmet need for highly purified, concentrated proteins for use in vaccine development and serological based diagnostic assays. To achieve this, the company has employed its novel VirTuETM platform which is based entirely on human cell lines using state-of-the-art expression techniques. Dr Holger Hannemann, Lead Scientist at The Native Antigen Company said: "Our aim was to focus on NS1's native hexameric presentation. The hexamer is believed to be the biologically active form of NS1 involved in key aspects of dengue pathogenesis. The resultant DENV NS1 proteins are purified to a high degree, are in their native folding state, and possess all post-translational modifications. This advanced approach results in a product which delivers optimal antigenicity due to its human origin".
"For several of our dengue research projects at the University of California, Berkeley, we had been searching for purified DENV NS1 protein from all four serotypes which could offer the advantage of being derived from a mammalian expression system. In our hands, NAC's DENV NS1 proteins have performed extremely well in a range of applications and have helped advance our research program"
Professor Eva Harris, Division of Infectious Diseases and Vaccinology, School of Public Health at the University of California, Berkeley
With more than one-third of the world's population living in areas at risk of transmission, dengue infection is a leading cause of illness and death in the tropics and subtropics. As many as 100 million people are infected yearly. Dengue is caused by any one of four related viruses transmitted by mosquitoes. There are no vaccines available to prevent infection with dengue virus.
Dengue Virus NS1
24/07/13. The Native Antigen Company (NAC) announces the release of its Dengue Virus serotype 1 NS1 protein (DENV1 NS1). Following the successful launch of its DENV2 NS1 protein, NAC has now added a further serotype, DENV1 NS1 to its portfolio. Both antigens have been manufactured in response to the unmet need for a highly purified, concentrated protein for use in vaccine development and serological based diagnostic assays. To achieve this, the company has employed its novel VirTuETM platform which is based entirely on human cell lines using state-of-the-art expression techniques. The resultant DENV1 and DENV2 NS1 proteins are purified to a high degree, are in their native folding state, and possess all post-translational modifications. This advanced approach offers a product which delivers optimal antigenicity. With more than one-third of the world's population living in areas at risk of transmission, dengue infection is a leading cause of illness and death in the tropics and subtropics. As many as 100 million people are infected yearly. Dengue is caused by any one of four related viruses transmitted by mosquitoes. There are no vaccines available to prevent infection with dengue virus. To cover the full spectrum of serotypes, NAC plans to launch both DENV3 and DENV4 NS1 proteins within the next 3 months.
Clostridium difficile ribotype 027 and 078 toxins
02/04/13. The Native Antigen Company (NAC) announces the release of highly purified toxins and toxoids from Clostridium difficile ribotypes 027 and 078 for use in research, vaccine development and by IVD manufacturers. Clostridium difficile infection (CDI) is a major cause of morbidity and mortality in economically developed countries. CDI is primarily linked with hospital admission and prior antimicrobial treatment. Although significant advances have been made to reduce incidence, a number of hypervirulent and highly transmissible strains have recently emerged. Resultant healthcare challenges are compounded as widespread use of antibiotics encourages both the emergence of resistant strains and reoccurrence of infection, especially in the elderly. The availability of these cost effective, high performance toxins and toxoids is timely and supports the increasing healthcare focus on combating these hypervirulent strains. To satisfy a broad range of applications, the products are offered as separate preparations in a variety of vial sizes and are suitable for long term storage.
Bordetella pertussis Filamentous Hemagglutinin (FHA) Antigen
03/02/12 - The Native Antigen Company (NAC) announces the release of its high purity Filamentous Hemagglutinin (FHA) Antigen. Extracted from Bordetella pertussis and purified to a very high degree (>98%) with minimal degradation, FHA is often used in combination with pertussis toxin for diagnostic screening purposes.
High purity Cytomegalovirus Antigen
03/01/12 - The Native Antigen Company (NAC) announces the release of a highly purified Cytomegalovirus antigen. The product has been developed in response to the in vitro diagnostics (IVD) industries requirement for a cost effective antigen which can demonstrate a high affinity for not only IgG but perhaps more importantly, for IgM. This antigen from NAC’s rapidly increasing portfolio also minimizes cross-reactivity and lot to lot variation. The company is well equipped to meet an anticipated high volume requirement from IVD manufacturers who major in this field. Presently, CMV infection is mostly controlled in immunocompromised patients by available antiviral drugs, yet it continues to maintain its role as one of the most dangerous infectious agents for the unborn infant. Primary infection is consistently associated with the presence of a virus specific IgM antibody response. NAC expects that use of its CMV native antigen will aid in improving serology based assays for early detection.
High purity Bordetella pertussis Toxin
08/11/11 - The Native Antigen Company (NAC) announces the release of a highly purified Bordetella pertussis toxin. The product has been developed in response to the increasing pressure on the IVD industry to supply highly specific, cost effective antibody capture systems, which are needed for monitoring vaccination programmes. FHA, a major cause of false results, is absent from the preparation. Manufacturing procedures are geared to ensure minimal lot to lot variation. The toxin is offered in lyophilised format for ease of storage and use. Pertussis (whooping cough), caused by Bordetella pertussis, is a major cause of childhood morbidity and mortality. There is evidence of a high burden of pertussis in developing countries and it remains one of the worlds leading causes of vaccine-preventable deaths. An estimated 50 million cases and 300 000 deaths occur every year with case-fatality rates in developing countries estimated to be as high as 4% in infants. The rationale for pertussis surveillance is to monitor the impact of the immunization system, identify high-risk areas and detect outbreaks which can then be investigated.
High purity Mycoplasma pneumoniae native antigen
02/10/11 - The Native Antigen Company (NAC) announces the release of a highly purified Mycoplasma pneumoniae native antigen. M. pneumoniae is recognized as one of the most common causes of community-acquired pneumonia. Early diagnosis of M. pneumoniae, usually by an ELISA IgM assay, is important because the infection often responds well to appropriate antibiotics. However, ELISA assays, particularly those for IgM detection, often exhibit poor sensitivity and may, in addition, be susceptible to cross reactivity from other pathogens. The company claims that its new purified antigen preparation, which is highly reactive to IgM, will offer in-vitro diagnostic (IVD) manufacturers the opportunity to introduce next generation ELISA assays which demonstrate greater specificity set against an inherently low background signal.
High purity Clostridium difficile Toxins & Toxoids
19/05/11 - The Native Antigen Company announces the release of high purity: C difficile toxins A & B to satisfy the increasing demands of vaccine research and bioprocess. To meet the needs for use as an immunogen or as a control, toxoid preparations are also available. All are offered as a lyophilised preparation to confer long term storage and are available in a choice of vial sizes.
Native Antigens to improve diagnostic testing of Acute Infantile Gastroenteritis
28/03/11 - The Native Antigen Company announces the release of a native antigen preparation to help improve the diagnosis of acute infantile gastroenteritis. Adenovirus type 40 (Ad40) is a group F Adenovirus and is a major cause of acute infantile gastroenteritis. Infection occurs worldwide and has been associated with 4-17% of cases of diarrhoea in children. Used as either as a positive control or as a means to capture antibodies to Ad40, the native antigen will help manufacturers to develop highly sensitive diagnostic assays. This will enable accurate diagnosis in routine work and make possible the evaluation of the role of this enteric adenovirus in diarrhoeal disease in the developing countries.
04/11/10 - The Native Antigen Company (NAC) is pleased to announce the launch of their first Astrovirus product. This is a challenging virus to grow and inactivate; but with optimised SOPs were are pleased to release a choice of formulations that can now be offered. Please check out our Native Antigen products page for more details, or contact us to enquire about how we can help tailor this antigen to your specific needs.